COVID-19 treatment: Antibody cocktail used to treat Donald Trump is helping patients in India; here's how

-

A Delhi hospital reported that two patients who were administered monoclonal antibodies showed remarkable recovery from the onset of symptoms of Covid-19 and were discharged within hours following the beginning of the treatment. Here’s how monoclonal antibodies work and why all eyes are on this therapy.

Monoclonal antibodies made news as a treatment for Covid-19 when they were given to former US President Donald Trump last year after he tested positive for the disease on the US election campaign trail. It was described at the time as an “experimental antibody cocktail" that the New York Times reported was “one of the most promising candidates". Initial results, the New York Times said, had “suggested that they can reduce the level of the virus in the body and possibly shorten hospital stays — when they are given early in the course of infection".

When US president received drug, it was an experimental therapy

The former US President had a low-grade fever, nasal congestion and a cough during his illness. Trump was deemed to be at high-risk for COVID-19 due to his age and weight. He spent a few days in hospital and was reported to have required supplemental oxygen at least twice. Apart from the antibody cocktail, Trump was given the antiviral drug remdesivir, and the steroid dexamethasone. He reported in a little more than a week that he had recovered and was not a risk for spreading the infection.

The former US President had a low-grade fever, nasal congestion and a cough during his illness. Trump was deemed to be at high-risk for Covid-19 due to his age and weight. He spent a few days in hospital and was reported to have required supplemental oxygen at least twice. Apart from the antibody cocktail, Trump was given the antiviral drug remdesivir, and the steroid dexamethasone. He reported in a little more than a week that he had recovered and was not a risk for spreading the infection.

When Trump was down with Covid-19, monoclonal antibodies hadn’t yet received authorisation in US for Covid-19 patients, but Regeneron, whose drug the former US president was given, got the nod in November last year.

What are monoclonal antibody therapies available in India?

The same Regeneron drug got emergency authorisation in India from the Central Drugs Standards Control Organisation (CDSCO) in early May. The cocktail — composed of Casirivimab and Imdevimab — was cleared for use in mild to moderate cases of Covid-19 in high-risk patients. It has been launched in India in partnership with Cipla and costs Rs 59,750 for each patient dose of 1200mg (600 mg of Casirivimab and 600 mg of Imdevimab).

Another drug, made by the US-based drugmaker Eli Lilly, too, has been cleared for use in India.

But monoclonal antibody therapies are not recommended for severe cases of Covid-19 where the patient has been hospitalised and on oxygen support.

So, what are monoclonal antibodies?

When our body is exposed to a pathogen, which is a virus or bacteria that can cause disease, our immunity system produces antibodies to counter it. As the name suggests, monoclonal antibodies are clones of these antibodies that are created in a lab. They are targeted towards countering a specific antigen, which is nothing but a foreign element that the immune system recognises to be a threat, prompting the production of antibodies.

The monoclonal antibodies used in the drug are artificially created in the laboratory and designed to bind to the spike protein of the novel coronavirus, which enables the virus to latch on to human cells.

While their initial use for Covid-19 patients was on an experimental basis, antibody treatments are nothing new and have been used in Ebola and HIV patients.



from Firstpost India Latest News https://ift.tt/3whKN13
Kenneth Kumar Mohanty

Comments

Post a Comment

Popular posts from this blog

Both COVID-19 vaccine doses needed for good protection against B16172 variant

-
It’s been a concerning few weeks in the UK, with the B16172 variant first taking hold and then spreading to become dominant. This more infectious form of the virus, initially identified in India, is what we’re now going to have to live with – unless it is out-competed by another variant in the future. Worryingly, experts had predicted that B16172 might be able to escape some of the effects of vaccines, which if true would threaten to derail the UK’s plans to finish lifting restrictions from the end of June. However, Public Health England (PHE) has looked at the ability of various variants to evade immunity and says that the UK’s vaccines remain effective against the variants circulating, including B16172. On the surface, this looks like good news. But delve a bit deeper, and things get more complicated, says Paul Hunter, professor of medicine at the University of East Anglia. PHE’s research found a little drop-off in protection against B16172 among people who were fully vaccinated.
Read more

New coronavirus variant emerge in India: How should our COVID response change?

-
Image
After genome sequencing of over 10,000 COVID-19 cases in India, researchers have discovered a new variant with two new mutations which may be better at evading the immune system. In 15-20 percent of samples from the Indian state of Maharashtra (the state accounting for 62 percent of cases in the country) a new, double mutation in key areas of the virus has been detected. These are now known as the E484Q and L452R mutations. What makes the variant different? Both these mutations are concerning because they are located in a key portion of the virus – the spike protein – that it uses to penetrate human cells. Spike proteins attach via a “receptor binding domain”, meaning the virus can attach to receptors in our cells. These new mutations include changes to the spike protein that make it a “better fit” for human cells. This means the virus can gain entry more easily and multiply faster. Given what we have seen with other similar mutations , it might also make it harder for our immu
Read more

Aditya L1 Mission: Spacecraft is nearing its final phase, says ISRO chief

-
Aditya L1 spacecraft is nearing its final phase, and manoeuvres to enter the L1 point are expected to be completed by January 7, 2024, according to ISRO Chairman S Somanath. “Aditya is on the way. I think it has reached almost its final phase,” the ISRO chief told PTI on the sidelines of an event organised at VSSC to commemorate the 60th year of the First Sounding Rocket Launch. Aditya L1, India’s first space-based mission to study the Sun, was successfully launched on September 2 from the Satish Dhawan Space Centre (SDSC) in Sriharikota. The spacecraft, after travelling about 1.5 million km from Earth over 125 days, is expected to be placed in a Halo orbit around the Lagrangian point L1, considered closest to the Sun. He said that the last preparations for the spacecraft’s entry into the L1 point are currently underway incrementally.”Possibly by January 7th, the final manoeuvres will be done for entering into the L1 point,” Somanath added. Among other tasks, it will capture and tr
Read more